Thomas Lang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Thomas Lang has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
A. Athari
Univar Solutions B.V, Rotterdam, Niederlande
1 shared publication- Anjana Grandhi
Merck & Co. Inc., Rahway, New Jersey, USA
1 shared publication - Barbara Haber
Merck & Co., Inc., Kenilworth, NJ, USA
1 shared publication Barbara Klostermann
Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center, Technical University of Munich, Lazarettstr. 36, D-80636 Munich, Germany
1 shared publication- Björn Fischler
Department of Pediatrics, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden
1 shared publication C. Kruse
Univar Solutions BV, Rotterdam, Niederlande
1 shared publication
Latest Publications
- 11 August 2023
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 61 (08) , e446-e447
TRISTAN – a Secondary Use of Data (SUD), retrospective real world data acquisition for therapy management of Wilson Disease Patients in Germany
Introduction Wilson disease (WD) is a rare autosomal recessively inherited disorder of copper metabolism with pathological copper accumulation mainly in the liver and brain. Chelators are mainly used as treatment for WD. In Germany D-penicillamine is approved as first-line treatment and Trientine (Trientine dihydrochloride (TETA-2HCl) and Trientine tetrahydrochloride (TETA-4HCL)), is available for patients who are intolerant to D-penicillamine. Data on therapy management of patients, specifically with respect to treatment switch and dosing, is rare. Aim This secondary use of data (SUD) project aims to assess retrospective real-world data regarding the diagnostic and therapeutic management, duration, sequence, and dosing of the different therapeutic options in specialized WD centres in Germany. Method In this project, anonymized data from WD patients who received Trientine therapy at least once during their course of treatment in the period of 1.01.2012 and 31.12.2021 and had one or more documented follow-up visits will be included. During the observation period D-Penicillamine, Zinc and two formulations of Trientine (TETA-2HCl and TETA-4HCl) were available. We aim to include 6 German WD centers and up to 150 patients. A questionnaire will be used to capture centre structure, WD diagnoses and therapeutic standards. Additionally, a second questionnaire will collect data for each suitable patient regarding the disease and therapy history. This includes all previous and the current treatments, switching between therapies, the duration of the treatments as well as the duration of the de-coppering phase and the maintenance phase. Furthermore, the dosage of said therapies during de-coppering and maintenance phase will be provided. Results The obtained data will be analysed using exploratory analysis (descriptive analysis/graphical display) based on the various aspects of the treatment management of WD patients. This includes demographic values as well as the number of treatment sequences, dosages prescribed during the different sequences and comparing the de-coppering and maintenance phase. Furthermore, a possible influence of the demographic factors and symptomatic classifications on therapy management will be investigated. Conclusion This project will contribute to a better understanding of the therapy management of WD patients in German specialized WD centres and might support physicians in future therapy decisions. Article published online: 28 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 11 August 2023
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 61 (08) , e446-e447
TRISTAN – a Secondary Use of Data (SUD), retrospective real world data acquisition for therapy management of Wilson Disease Patients in Germany
Introduction Wilson disease (WD) is a rare autosomal recessively inherited disorder of copper metabolism with pathological copper accumulation mainly in the liver and brain. Chelators are mainly used as treatment for WD. In Germany D-penicillamine is approved as first-line treatment and Trientine (Trientine dihydrochloride (TETA-2HCl) and Trientine tetrahydrochloride (TETA-4HCL)), is available for patients who are intolerant to D-penicillamine. Data on therapy management of patients, specifically with respect to treatment switch and dosing, is rare. Aim This secondary use of data (SUD) project aims to assess retrospective real-world data regarding the diagnostic and therapeutic management, duration, sequence, and dosing of the different therapeutic options in specialized WD centres in Germany. Method In this project, anonymized data from WD patients who received Trientine therapy at least once during their course of treatment in the period of 1.01.2012 and 31.12.2021 and had one or more documented follow-up visits will be included. During the observation period D-Penicillamine, Zinc and two formulations of Trientine (TETA-2HCl and TETA-4HCl) were available. We aim to include 6 German WD centers and up to 150 patients. A questionnaire will be used to capture centre structure, WD diagnoses and therapeutic standards. Additionally, a second questionnaire will collect data for each suitable patient regarding the disease and therapy history. This includes all previous and the current treatments, switching between therapies, the duration of the treatments as well as the duration of the de-coppering phase and the maintenance phase. Furthermore, the dosage of said therapies during de-coppering and maintenance phase will be provided. Results The obtained data will be analysed using exploratory analysis (descriptive analysis/graphical display) based on the various aspects of the treatment management of WD patients. This includes demographic values as well as the number of treatment sequences, dosages prescribed during the different sequences and comparing the de-coppering and maintenance phase. Furthermore, a possible influence of the demographic factors and symptomatic classifications on therapy management will be investigated. Conclusion This project will contribute to a better understanding of the therapy management of WD patients in German specialized WD centres and might support physicians in future therapy decisions. Article published online: 28 August 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S308-S309
ERCP in infants, children and adolescents – Experiences of a pediatric centre
Aims ERCP in children older than 3 years and adolescents is a common procedure for detecting and treating congenital or acquired biliopancreatic disorders. For infants younger than 3 months ERCP represents a complex and challenging technique to diagnose or treat rare, mostly congenital diseases. Still there is poor data regarding diagnostic yield, therapeutic outcome and above all the savety of ERCP in infants younger than 3 months. Methods To investigate this, we conducted a retrospective analysis of 90 ERCPs in 63 children between Jan. 2019 and Dec. 2021. Aim was to assess the indication for ERCPs, the diagnostic and therapeutic outcome as well as the rate of adverse events during and after the procedures. Results Over a course of two years a total of 63 consecutive children (mean age 2.88 years, median 0.17 years, 45% girls) underwent 90 ERCPs. 37 children (58%) were younger than 3 months, 28 children (29%) were between 3 months and 6 years and 8 children (13%) were older than 6 years. The main reasons for ERCPs in infants were congenital disorders, such as bile duct astresia or hypoplasia. In children and adolescents ERCP was indicated because of congenital and acquired disorders (gallstones, hereditary pancreatitis). The mean duration of ERCPs overall was 40.7 minutes (diagnostic 30.3 minutes, therapeutic 51.1 minutes). Complications occured in 7 cases (7.7%): 1 post ERCP pancreatitis, 4 mild cholangitis, 1 endotracheal re-intubation due to respiratory insufficiency after procedure [1] [2] [3] [4] [5] [6]. Conclusions In this large retrospective cohort study we were able to show that pediatric ERCP is a feasible, effective and save procedure, even in infants younger than 3 months. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S308-S309
ERCP in infants, children and adolescents – Experiences of a pediatric centre
Aims ERCP in children older than 3 years and adolescents is a common procedure for detecting and treating congenital or acquired biliopancreatic disorders. For infants younger than 3 months ERCP represents a complex and challenging technique to diagnose or treat rare, mostly congenital diseases. Still there is poor data regarding diagnostic yield, therapeutic outcome and above all the savety of ERCP in infants younger than 3 months. Methods To investigate this, we conducted a retrospective analysis of 90 ERCPs in 63 children between Jan. 2019 and Dec. 2021. Aim was to assess the indication for ERCPs, the diagnostic and therapeutic outcome as well as the rate of adverse events during and after the procedures. Results Over a course of two years a total of 63 consecutive children (mean age 2.88 years, median 0.17 years, 45% girls) underwent 90 ERCPs. 37 children (58%) were younger than 3 months, 28 children (29%) were between 3 months and 6 years and 8 children (13%) were older than 6 years. The main reasons for ERCPs in infants were congenital disorders, such as bile duct astresia or hypoplasia. In children and adolescents ERCP was indicated because of congenital and acquired disorders (gallstones, hereditary pancreatitis). The mean duration of ERCPs overall was 40.7 minutes (diagnostic 30.3 minutes, therapeutic 51.1 minutes). Complications occured in 7 cases (7.7%): 1 post ERCP pancreatitis, 4 mild cholangitis, 1 endotracheal re-intubation due to respiratory insufficiency after procedure [1] [2] [3] [4] [5] [6]. Conclusions In this large retrospective cohort study we were able to show that pediatric ERCP is a feasible, effective and save procedure, even in infants younger than 3 months. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 14 February 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (3) , e0031
Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
Background: Approximately 3.5 million children and adolescents worldwide are chronically infected with HCV. This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir (EBR/GZR) that achieve plasma concentrations similar to those seen in adults receiving the approved fixed-dose combination regimen of EBR/GZR. Patients and Methods: We conducted a nonrandomized, single-arm, multicenter, open-label phase 2b trial in children and adolescents aged 3 to <18 years with chronic HCV genotype 1 or 4 infection (NCT03379506). Pharmacokinetic data were used to bridge efficacy and safety data from adults to children in a stepwise (oldest to youngest) manner. A total of 57 participants were enrolled: cohort 1 (aged 12 to <18 y), n=22; cohort 2 (aged 7 to <12 y), n=17; and cohort 3 (aged 3 to <7 y), n=18. Results: Steady-state plasma exposures were achieved by week 4 for EBR and GZR in all cohorts and daily dosing achieved geometric mean steady-state area under the concentration-time curve at 0–24 hours that fell within comparability bounds established for adults. All participants achieved sustained virologic response 12 weeks after completing treatment (ie, undetectable HCV RNA 12 wk following completion of treatment). Headache (n=4), fatigue (n=4), and nausea (n=2) were the most common treatment-related adverse events (all mild or moderate); no participant discontinued because of an adverse event. Conclusions: Pediatric EBR/GZR pharmacokinetic models were successfully developed based on complex adult population pharmacokinetic models. At appropriate age-related doses, EBR/GZR is safe and effective in pediatric and adolescent participants with HCV infection.
- 14 February 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (3) , e0031
Open AccessElbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
Background: Approximately 3.5 million children and adolescents worldwide are chronically infected with HCV. This study uses pharmacokinetic modeling to identify pediatric doses of elbasvir/grazoprevir (EBR/GZR) that achieve plasma concentrations similar to those seen in adults receiving the approved fixed-dose combination regimen of EBR/GZR. Patients and Methods: We conducted a nonrandomized, single-arm, multicenter, open-label phase 2b trial in children and adolescents aged 3 to <18 years with chronic HCV genotype 1 or 4 infection (NCT03379506). Pharmacokinetic data were used to bridge efficacy and safety data from adults to children in a stepwise (oldest to youngest) manner. A total of 57 participants were enrolled: cohort 1 (aged 12 to <18 y), n=22; cohort 2 (aged 7 to <12 y), n=17; and cohort 3 (aged 3 to <7 y), n=18. Results: Steady-state plasma exposures were achieved by week 4 for EBR and GZR in all cohorts and daily dosing achieved geometric mean steady-state area under the concentration-time curve at 0–24 hours that fell within comparability bounds established for adults. All participants achieved sustained virologic response 12 weeks after completing treatment (ie, undetectable HCV RNA 12 wk following completion of treatment). Headache (n=4), fatigue (n=4), and nausea (n=2) were the most common treatment-related adverse events (all mild or moderate); no participant discontinued because of an adverse event. Conclusions: Pediatric EBR/GZR pharmacokinetic models were successfully developed based on complex adult population pharmacokinetic models. At appropriate age-related doses, EBR/GZR is safe and effective in pediatric and adolescent participants with HCV infection.
- 1 July 2006
- Published by Elsevier in Journal of Infection
- Vol. 53 (1) , 43-48
Prevalence and clinical role of GBV-C infection after cardiac surgery in childhood: A study on 414 patients
- 1 July 2006
- Published by Elsevier in Journal of Infection
- Vol. 53 (1) , 43-48
Prevalence and clinical role of GBV-C infection after cardiac surgery in childhood: A study on 414 patients